Patchai has been added to the Top 100 Digital Health Companies selected by The Medical Futurist. We are honored to be part of this list that offers a complete picture of the digital health business market. The magazine evaluated four key features that companies venturing into digital health must possess:
mindset for innovation;
truly disruptive technology;
viable business model;
clear dedication to digital health.
We would like to thank The Medical Futurist. We can reflect in the four values of its Top 100 List, as our mission is to build an innovative digital solution that can improve healthcare systems around the world.
Digital Health: the Scenario
The global digital health market continues its growth with a forecast of $660bn value by 2025, while 2020 was a record-setting year with unprecedented investments. On the other hand healthcare institutions don’t keep the same pace. According to a report1 from the Center of Connected Medicine and Klas, between May and June 2021, only 20% of visits were performed virtually by the surveyed companies.
With the global pandemictelehealth applications have been optimized to remotely monitor patients while avoiding Covid-19 spread. We need to learn from this important lesson and don’t look back the old normal procedures, even if they are well consolidated.
Patchai, the digital health assistant
Patchai solutions bridge patients' and clinicians’ needsduring clinical trials and offer a more efficient system while engaging patients at every step of the research. Patchai's software solutionsapply also to standard care routines significantly improving the patient experience. Thanks to our proprietary Co-PRO technologies and the AI virtual assistant Pat, Patchai creates the ideal patient journey, collects Real World Evidence, and maintains regulatory compliance.
Patchai develops intelligent digital health engagement solutions for decentralized clinical studies. The company has received funding under the Smart&Start Italia program. The funding supported the company to develop its clinical research and standard care platforms and to internalize core functions (IT, business development, marketing&sales, medical affairs, clinical operations, human resources). The company will continue to advance the predictive capabilities of the CO-PRO® technology and the IoT integration of its products.